Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 240,400 shares, an increase of 450.1% from the December 31st total of 43,700 shares. Based on an average daily trading volume, of 2,980,000 shares, the short-interest ratio is currently 0.1 days. Currently, 2.9% of the company’s stock are short sold.

Revelation Biosciences Stock Up 11.2 %

Shares of REVB stock traded up $0.43 on Tuesday, reaching $4.24. The stock had a trading volume of 613,538 shares, compared to its average volume of 493,136. Revelation Biosciences has a 12 month low of $3.61 and a 12 month high of $404.16. The firm has a market capitalization of $18.19 million, a price-to-earnings ratio of -0.25 and a beta of 0.24. The firm’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.87.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.